A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts

Abstract

BackgroundSystemic inflammation is a whole body reaction having an infection-positive (i.e., sepsis) or infection-negative origin. It is important to distinguish between these two etiologies early and accurately because this has significant therapeutic implications for critically ill patients. We hypothesized that a molecular classifier based on peripheral blood RNAs could be discovered that would (1) determine which patients with systemic inflammation had sepsis, (2) be robust across independent patient cohorts, (3) be insensitive to disease severity, and (4) provide diagnostic utility. The goal of this study was to identify and validate such a molecular classifier.Methods and FindingsWe conducted an observational, non-interventional study of adult patients recruited from tertiary intensive care units (ICUs). Biomarker discovery utilized an Australian cohort (n = 105) consisting of 74 cases (sepsis patients) and 31 controls (post-surgical patients with infection-negative systemic inflammation) recruited at five tertiary care settings in Brisbane, Australia, from June 3, 2008, to December 22, 2011. A four-gene classifier combining CEACAM4, LAMP1, PLA2G7, and PLAC8 RNA biomarkers was identified. This classifier, designated SeptiCyte Lab, was validated using reverse transcription quantitative PCR and receiver operating characteristic (ROC) curve analysis in five cohorts (n = 345) from the Netherlands. Patients for validation were selected from the Molecular Diagnosis and Risk Stratification of Sepsis study (ClinicalTrials.gov, NCT01905033), which recruited ICU patients from the Academic Medical Center in Amsterdam and the University Medical Center Utrecht. Patients recruited from November 30, 2012, to August 5, 2013, were eligible for inclusion in the present study. Validation cohort 1 (n = 59) consisted entirely of unambiguous cases and controls; SeptiCyte Lab gave an area under curve (AUC) of 0.95 (95% CI 0.91–1.00) in this cohort. ROC curve analysis of an independent, more heterogeneous group of patients (validation cohorts 2–5; 249 patients after excluding 37 patients with an infection likelihood of “possible”) gave an AUC of 0.89 (95% CI 0.85–0.93). Disease severity, as measured by Sequential Organ Failure Assessment (SOFA) score or Acute Physiology and Chronic Health Evaluation (APACHE) IV score, was not a significant confounding variable. The diagnostic utility of SeptiCyte Lab was evaluated by comparison to various clinical and laboratory parameters available to a clinician within 24 h of ICU admission. SeptiCyte Lab was significantly better at differentiating cases from controls than all tested parameters, both singly and in various logistic combinations, and more than halved the diagnostic error rate compared to procalcitonin in all tested cohorts and cohort combinations. Limitations of this study relate to (1) cohort compositions that do not perfectly reflect the composition of the intended use population, (2) potential biases that could be introduced as a result of the current lack of a gold standard fo...

Diagnosing antimicrobial resistance

“…These multidisciplinary approaches are crucial if better diagnostics are to be developed and implemented in clinical microbiology. An example of a potential area for future multidisciplinary collaboration is combining the detection of human biomarkers of infection, such as blood transcriptional biomarkers 11 , with the detection of the pathogen and the antimicrobial resistance profile in a single test. For example, using host and pathogen metatranscriptomics for the diagnosis of sepsis could determine whether an infection is present and, if an infection is present, could guide appropriate antimicrobial therapy.…”

New Molecular Diagnostic Approaches to Bacterial Infections and Antibacterial Resistance

“…15–18 One test is recently FDA cleared for sepsis (SeptiCyte LAB) 19 , but is not yet commercially available. Gene expression-based diagnostics in infectious diseases have been limited by the need to provide rapid, simple, point-of-need results in the setting of potentially life-threatening infection.…”

Host-Based Peripheral Blood Gene Expression Analysis for Diagnosis of Infectious Diseases

“…Distinguishing whether SIRS is due to an infectious (i.e., sepsis) or a noninfectious etiology is of immediate and critical importance. To date, peripheral bloodderived gene expression-based classifiers have proven capable of distinguishing sepsis from SIRS with excellent diagnostic accuracy, including a 4-gene signature that demonstrated a sensitivity of 79% and a specificity of 91% (14). After distinguishing sepsis from SIRS, the next important task for clinicians is to subclassify septic patients across the spectrum of pathogen classes and degrees of clinical severity in order to personalize treatment decisions.…”